



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 19, 2020

Jason A. Amello  
Chief Financial Officer  
Akebia Therapeutics, Inc.  
245 First Street  
Cambridge, MA 02142

**Re: Akebia Therapeutics, Inc.  
Form 10-Q for the quarterly period ended September 30, 2019  
Exhibit No. 10.2 - Waiver and First Amendment to Loan Security and Security  
Agreement, dated as of July 31, 2019, by and between Keryx Biopharmaceuticals, Inc.  
and Silicon Valley Bank  
Exhibit No. 10.3 - Security Agreement, dated as of August 7, 2019, by and between  
Akebia Therapeutics, Inc. and Silicon Valley Bank  
Filed November 12, 2019  
File No. 001-36352**

Dear Mr. Amello:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance